High-penetrance (BRCA1, BRCA2, CDH1, PALB2, PTEN, TP53) and moderate-penetrance (ATM, BARD1, BRIP1, CHEK2, MLH1, MSH2, MSH6, NF1, PMS2, RAD51C, RAD51D) tumour susceptibility genes were selected according to NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 2023.3 guideline. This evidence concerns the gene PTEN and neoplasm.